

Myelin Oligodendrocyte Glycoprotein Antibody Associated Acute Disseminated Encephalomyelitis Post Varicella Infection in a Child: A Case Report

SHIKHA YADAV¹, JYOTI KADIAN², HARDIK SONI³, RITIKA SINGH⁴, KAPIL BHALLA⁵

 CC BY-NC-ND

ABSTRACT

Myelin Oligodendrocyte Glycoprotein Antibody associated Disease (MOGAD), an autoimmune demyelinating disorder, often overlaps with features of Acute Disseminated Encephalomyelitis (ADEM), optic neuritis and transverse myelitis in paediatric population. Recent advances have identified Myelin Oligodendrocyte Glycoprotein (MOG) antibody as a marker in a subset of paediatric demyelinating diseases. MOGAD is increasingly being recognised as a distinct entity among paediatric demyelinating disorders. Identification of MOG antibodies is important as it has diagnostic, therapeutic and prognostic implications particularly in post-infectious demyelination. Herein, the authors report a case of 10-year-old male who presented with fever and vesicular lesions for 10 days, suggesting chickenpox infection (varicella), which was followed by paraparesis. Neurological examination suggested hypotonia of lower limbs and absent deep tendon reflexes with rest of central nervous examination within normal limits. Radiological and biochemical investigations (serum MOG positive) confirmed the diagnosis of ADEM likely to be post varicella infection. He was managed successfully with intravenous immunoglobulin, high dose steroids and is currently doing well on follow-up. This case highlights the importance of early detection, diagnosis and testing for anti-MOG in children presenting with ADEM like features. Early recognition of MOG antibody associated ADEM and timely initiation of immunotherapy are crucial for improving neurological outcomes in affected children. This case emphasises the need to consider MOGAD in children presenting with acute demyelination after varicella.

Keywords: Chicken pox, Demyelinating, Hyperintensity, Optic neuritis, Paraparesis

CASE REPORT

A 10-year-old previously healthy male child presented to the paediatric outpatient department with fever and vesicular skin lesions over the face which later spread to trunk and extremities over the next 10 days. The fever was documented, high grade, with two-three spikes per day. The rash resolved with crusting of lesions approximately in 10 days, consistent with diagnosis of chickenpox. Two days after resolution of the rash he developed fever followed by weakness in bilateral lower limbs, inability to walk and not passing urine since morning prior to admission. There was no family history of neurological disorder, no prior hospital admissions.

On physical examination, the child was febrile (102°F), and blood pressure, respiratory rate, pulse rate were normal. A detailed neurological examination revealed hypotonia and weakness in both lower limbs. Muscle power was graded 2/5 bilaterally. Deep tendon reflexes, including the knee and ankle jerks, were absent, and the Babinski sign was negative. There was no history of unconsciousness, abnormal body movements, no cranial nerve palsy or eye movement abnormalities. Upper limb power and deep tendon reflexes were normal. Rest of the systemic examination including cardiovascular, respiratory and abdominal system was normal. Considering above findings, a provisional diagnosis of post infectious acute transverse myelitis was kept.


The child was started on intravenous fluids (as per the Holliday–Segar formula), along with intravenous antibiotics—ceftriaxone (100 mg/kg/day) and vancomycin (80 mg/kg/day) for 10 days—and acyclovir (20 mg/kg/dose) administered eight-hourly. He was catheterised for monitoring of urinary output and investigations were planned. Routine investigations sent, were within normal limits [Table/Fig-1]. Neuroimaging by contrast enhanced MRI Brain and spine showed

short segment T2 hyperintense signal in cervical cord from C5-C7 levels, long segment T2 hyperintense signal in thoracic cord post contrast enhancement and subtle white matter hyperintensities in pons and midbrain, indicating features of ADEM [Table/Fig-2]. Cerebrospinal Fluid (CSF) analysis revealed protein 47 mg/dL, glucose 62 mg/dL and no pleocytosis or oligoclonal bands. Serum MOG-IgG antibodies were positive by a cell-based immunofluorescence assay. CSF analysis showed no oligoclonal bands thereby ruling out Multiple Sclerosis (MS). Additionally Visual Evoked Potential (VEP) was normal suggesting no evidence of optic neuritis. The pattern of weakness ruled out Guillain Barre syndrome and preserved consciousness ruled out the possibility of viral encephalitis. Based on above findings, a diagnosis of post-chickenpox ADEM associated with MOG antibody positivity was made.

Test	Values	Normal range
Haemoglobin (g/dL)	12	12.5-16.1
TLC (cells/ μ L)	13700	4000-10500
Platelet count (lacs)	4.5	1.5-4
Blood urea (mg/dL)	24	15-45
Serum creatinine (mg/dL)	0.6	0.3-0.88
SGOT (U/L)	24	10-40
SGPT (U/L)	20	10-40
S.AL.P (U/L)	116	150-560
S.Ca (mg/dL)	10.2	8.8-10.8
S.Phosphorus (mg/dL)	5.6	3.7-5.6
S.Sodium (mEq/L)	136	135-145
S.Potassium (mEq/L)	3.7	3.5-4.6
CSF Protein (mg/dL)	47	20-45

CSF Sugar (mg/dL)	62	>75% of serum glucose
CSF Cytology	Acellular	<5 cells
CSF Culture	Sterile	No growth/sterile
CSF Neuro-viral panel	Negative	Negative
ESR (mm/hr)	22	<20
Serum NMO MOG panel	Anti MOG IgG antibody positive	
Anti Aquaporin-4 (NMO) IgG antibodies	Negative	

[Table/Fig-1]: Summary of investigations.



[Table/Fig-2]: Contrast Enhanced MRI Brain and spine showing (yellow arrow) short segment T2 hyperintense signal in cervical cord from C5-C7 levels, long segment (blue arrow) T2 hyperintense signal in thoracic cord post-contrast enhancement.

DISCUSSION

The ADEM is an inflammatory demyelinating event, typically monophasic, occurring predominantly in children preceded by viral infections such as varicella, measles mumps, rubella. Approx 50% of ADEM cases show MOG-IgG positivity. While varicella (chickenpox) infection in children is a recognised trigger for ADEM, neurological complications occur in less than 1% of varicella cases, post-varicella MOG-IgG-associated ADEM remains exceedingly rare with an incidence of 0.5-1 per 100,000 population [1-3]. Post-infectious immune activation is considered the key mechanism, where molecular mimicry between viral antigens and myelin components leads to an aberrant immune response [4].

Bhandari S et al., reported a case post-chickenpox MOG antibody-associated ADEM presenting with quadriplegia following varicella infection, similar to the present case where neurological symptoms followed a short latent period after chickenpox. However, their patient had involvement of all four limbs, whereas the present case predominantly involved the lower limbs with bladder dysfunction [5]. Yadav A et al., reported a teenage patient who developed ADEM following varicella infection with positive MOG antibodies, who showed diffuse white matter changes on MRI and responded well to corticosteroid therapy. Similar MRI features and favourable response to immunotherapy were observed in the present case, supporting the monophasic nature of post-infectious MOGAD [6]. Hancock KAM et al., reported a case of a six-year-old boy who developed MOG-antibody (MOG-Ab) associated demyelinating syndrome, after initially presenting with aseptic meningitis. In contrast, the present case did not show meningeal features but presented with acute myelopathy, highlighting the phenotypic heterogeneity of paediatric MOGAD despite a shared autoimmune mechanism [7]. In the present case, the temporal relationship between varicella infection and neurological symptoms, along with positive anti-MOG antibodies, supports a diagnosis of post-varicella MOGAD, a rare entity [8]. MRI findings were consistent with ADEM showing diffuse bilateral white matter involvement. The absence of CSF oligoclonal bands in this patient further supports MOGAD rather than MS, since OCBs are typically negative or transient in MOGAD (<30%) but persistently positive in MS (>90%) [9,10].

Similarly, normal VEP ruled out optic neuritis, which is another common phenotype of MOGAD but was not evident in this case. In the present case, the patient responded well to IVIG and corticosteroids with near-complete recovery and no relapse on follow-up, suggesting a monophasic course. Treatment of MOGAD includes high-dose intravenous methylprednisolone for 3-5 days followed by a slow oral steroid taper over 6-8 weeks [11]. IVIg or plasmapheresis is considered in steroid-refractory case [12]. Long-term prognosis in paediatric MOGAD is generally favourable; however, 20-30% of patients may experience relapses, particularly when steroids are tapered rapidly or discontinued early [13]. Persistent antibody positivity may predict higher relapse risk, emphasising the need for close follow-up [14]. The present case highlights the importance of considering MOGAD in the differential diagnosis of demyelinating syndromes following viral infections such as varicella. Early recognition and immunotherapy are crucial for preventing permanent neurological sequelae. Given the overlap between post-infectious ADEM and MOGAD, testing for anti-MOG antibodies is essential in all children presenting with ADEM-like features.

CONCLUSION(S)

Authors report a case of MOG-antibody-associated ADEM following chickenpox in a child. This reinforces the need for MOG-IgG testing in post-viral demyelinating syndromes and highlights chickenpox as a potential autoimmune trigger. The presence of serum MOG-IgG supports classification within the MOG-associated demyelination spectrum, which presents with an ADEM phenotype in the paediatric

The patient was also managed with Intravenous Immunoglobulin (IVIG) (@2 g/kg) over five days and high dose intravenous methylprednisolone (@30 mg/kg/day) for five days followed by an oral steroids (2 mg/kg/day) to be tapered over six to eight weeks. The patient showed significant improvement during hospital stay with gradual recovery of power and bladder control. He was discharged after 14 days of hospitalisation and was followed-up at three months post discharge, when he remained asymptomatic with no residual neurologic deficits.

population. In this case the child demonstrated multifocal, bilateral white-matter involvement and concurrent spinal cord lesions following a recent viral illness. Early initiation of immunotherapy led to clinical improvement, highlighting the favourable outcome typically seen in paediatric MOG-associated ADEM when promptly treated. This case emphasises the need to consider MOGAD in children presenting with acute demyelination after varicella.

REFERENCES

- [1] Hacohen Y, Mankad K, Chong WK. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. *Neurology*. 2017;89(3):269-78.
- [2] Takai Y, Misu T, Kaneko K. Japan MOG-antibody Disease Consortium. Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study. *Brain*. 2020;143(5):1431-46.
- [3] Gupta S, Biswas A, Chandra A. Post-varicella neurological complications: A preliminary observation from a tertiary care centre of eastern India. *Ann Indian Acad Neurol*. 2022;25(2):207-13.
- [4] Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. *Nat Rev Neurol*. 2019;15(2):89-102.
- [5] Bhandari S, Khan N, Swami Y, Agrawal A, Gupta V, Wadhvani D. Acute onset quadriplegia as myelin oligodendrocyte glycoprotein (MOG) associated disease with ADEM after chicken pox – a rare case presentation. *Int J Sci Res*. 2023;12(3):62-64.
- [6] Yadav A, Sharma R, Ganiger MP, Sharma G. Anti-myelin oligodendrocyte glycoprotein antibody positive acute disseminated encephalomyelitis post-varicella zoster virus infection: A case report of a 15-year-old girl. *Ann Indian Acad Neurol*. 2021;24(5):797-99.
- [7] Hancock KA, Waters P, Woodhall M. MOG antibody-associated demyelinating syndrome presenting as aseptic meningitis in a 6-year-old boy. *J Neurol Sci*. 2020;417:117097.
- [8] Shoamanesh A, Traboulsee AL, Pettersen JA. Acute disseminated encephalomyelitis following varicella infection. *Can J Neurol Sci*. 2010;37(2):273-75.
- [9] Jarius S, Paul F, Aktas O. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. *J Neuroinflammation*. 2018;15(1):134.
- [10] Fadda G, Brown RA, Longoni G. MRI findings in MOG antibody-associated disease and comparison with AQP4-NMOSD and MS. *J Neurol Neurosurg Psychiatry*. 2021;92(3):317-25.
- [11] Narayan RN, Simpson A, Fritsche K. MOG antibody disease in children: Clinical features and outcomes. *J Child Neurol*. 2020;35(4):253-62.
- [12] Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotypes, and relevance in the modern era. *J Neurol Neurosurg Psychiatry*. 2016;87(3):268-79.
- [13] Armangue T, Olivé-Casas M, Pérez-Dueñas B. Myelin oligodendrocyte glycoprotein antibodies in children with acquired demyelinating syndromes: Clinical and radiologic correlations. *Mult Scler J*. 2020;26(2):240-52.
- [14] Di Pauli F, Mader S, Rostasy K. Temporal dynamics of MOG antibodies in CNS demyelinating diseases. *Clin Immunol*. 2011;138(3):247-54.

PARTICULARS OF CONTRIBUTORS:

1. Junior Resident, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.
2. Junior Resident, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.
3. Junior Resident, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.
4. Junior Resident, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.
5. Professor, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Shikha Yadav,
Junior Resident, Department of Paediatrics, Pt. B.D. Sharma PGIMS,
Rohtak-124001, Haryana, India.
E-mail: shikhayadav00564@gmail.com

PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Nov 19, 2025
- Manual Googling: Feb 14, 2026
- iThenticate Software: Feb 17, 2026 (2%)

ETYMOLOGY: Author Origin

EMENDATIONS: 6

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. Yes

Date of Submission: **Nov 17, 2025**

Date of Peer Review: **Jan 21, 2026**

Date of Acceptance: **Feb 19, 2026**

Date of Publishing: **Jun 01, 2026**